Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy

Journal of Hepatology

Volumn 51, Issue 1, 2009, Pages 224-226

  Janssen, Harry L A ^a   Buster, Erik H C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; NUCLEOSIDE ANALOG; PEGINTERFERON; VIRUS DNA;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; DRUG TOLERABILITY; HEPATITIS B; HUMAN; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ALANINE TRANSAMINASE; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; PRACTICE GUIDELINES AS TOPIC;

EID: 67349245219     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.02.012     Document Type: Letter

References (33)

1. van Nunen A.B., Hansen B.E., Suh D.J., Lohr H.F., Chemello L., Fontaine H., et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52 (2003) 420-424
2. Dienstag J.L., Cianciara J., Karayalcin S., Kowdley K.V., Willems B., Plisek S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37 (2003) 748-755
3. Song B.C., Suh D.J., Lee H.C., Chung Y.H., and Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
4. Chien R.N., Yeh C.T., Tsai S.L., Chu C.M., and Liaw Y.F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 (2003) 1267-1273
5. Gish R.G., Lok A.S., Chang T.T., de Man R.A., Gadano A., Sollano J., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (2007) 1437-1444
6. Poynard T., Hou J.L., Chutaputti A., Manns M., and Naoumov N. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine. J Hepatol 48 (2008) S263-S264
7. Ryu S.H., Chung Y.H., Choi M.H., Kim J.A., Shin J.W., Jang M.K., et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 39 (2003) 614-619
8. Buster E.H., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Tabak F., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology 135 (2008) 459-467
9. Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., and Hoofnagle J.H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114 (1991) 629-634
10. Krogsgaard K., The Long-Term Follow-up Investigator Group, The European Study Group on Viral Hepatitis (EUROHEP), and Executive Team on Anti-Viral Treatment. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 5 (1998) 389-397
11. Lau D.T., Everhart J., Kleiner D.E., Park Y., Vergalla J., Schmid P., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
12. Marcellin P., Piratvisuth T., Brunetto M.R., Bonino F., Lau G.K., Farci P., et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) with or without lamivudine: results of 4-year follow-up. J Hepatol 48 (2008) S46
13. van Zonneveld M., Honkoop P., Hansen B.E., Niesters H.G., Murad S.D., de Man R.A., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
14. Bonino F., Marcellin P., Lau G.K., Hadziyannis S., Jin R., Piratvisuth T., et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (2007) 699-705
15. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
16. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
17. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 10.1007/s12072-008-9080-3
18. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
19. Hadziyannis S., Lau G.K.K., Marcellin P., Piratvisuth T., Cooksley G., Bonino F., et al. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alpha-2a (40 kDa) (Pegasys®). J Hepatol 42 (2005) S178
20. Wai C.T., Chu C.J., Hussain M., and Lok A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36 (2002) 1425-1430
21. Erhardt A., Blondin D., Hauck K., Sagir A., Kohnle T., Heintges T., et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54 (2005) 1009-1013
22. Hou J., Schilling R., Janssen H.L.A., Hansen B.E., Heijtink R., Sablon E., et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-based HBeAg clearance. J Med Virol 79 (2007) 1055-1063
23. Kao J.H., Wu N.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33 (2000) 998-1002
24. Cooksley W.G.E., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., et al. Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
25. Buster E.H., Hansen B.E., Lau G.K., Piratvisuth T., McCloud P.I., Button P., et al. Prediction of response to peginterferon-alfa in HBeAg positive chronic hepatitis B: a model based on 721 patients. Hepatology 48 (2008) 723A-724A
26. Erhardt A., Ludwig A.D., Brunetto M., van Boemmel F., Wolf E., Goebel T., et al. HBV genotypes are the stongest predictors of response to interferon-alfa treatment: multivariate evaluation in 1229 hepatitis B patients. Hepatology 48 (2008) 700A-701A
27. ter Borg M.J., van Zonneveld M., Zeuzem S., Senturk H., Akarca U.S., Simon C., et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 44 (2006) 721-727
28. Fried M.W., Piratvisuth T., Lau G.K., Marcellin P., Chow W.C., Cooksley G., et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47 (2008) 428-434
29. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
30. Locarnini S., Qi X., Arterburn S., Snow A., Brosgart C.L., Currie G., et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B. J Hepatol 42 (2005) A17
31. Sherman M., Rizzetto M., Lai C.L., Liaw Y.F., Gadano A., Jacobson I.M., et al. Long-term follow-up of entecavir treated protocol-defined non-responders in rollover study ETV-901. Hepatology 46 (2007) 682A
32. Marcellin P., Buti M., Krastev Z., Gurel S., Balabanska R.I., Dusheiko G., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary results. Hepatology 48 (2008) 370A
33. Heathcote E.J., Gane E.J., de Man R.A., Chan S., Sievert W., Mauss S., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 48 (2008) 376A